CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.

Abstract:

:We investigated CD25 expression in older (≥60 years) patients with new acute myelogenous leukemia treated with decitabine and plerixafor. Patients resistant to therapy or survival ≤1 year had significantly higher percentages of CD25pos myeloid blasts in baseline bone marrow. CD25pos patients had an increased odds of resistance compared to CD25neg patients (p = .015). In univariate analysis, we found CD25pos patients had inferior survival compared to CD25neg (p = .002). In patients with intermediate risk cytogenetics, CD25pos status stratified patients associating with inferior survival (p = .002). In multivariable analysis, CD25 and TP53 mutations trended towards predicting remission to therapy but were not predictive of survival. Only remission status, ASXL1 and TET2 mutations were found to independently predict overall survival (OS). We conclude CD25 expression identifies patients at risk for resistance to hypomethylating chemotherapy but does not independently predict OS in an older AML population treated with decitabine and plerixafor.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Allan JN,Roboz GJ,Askin G,Ritchie E,Scandura J,Christos P,Hassane DC,Guzman ML

doi

10.1080/10428194.2017.1352089

subject

Has Abstract

pub_date

2018-04-01 00:00:00

pages

821-828

issue

4

eissn

1042-8194

issn

1029-2403

journal_volume

59

pub_type

杂志文章
  • T-cell and NK/T-cell lymphomas in southern Taiwan: a study of 72 cases in a single institute.

    abstract::In an attempt to better understand the clinicopathologic features of T- and natural killer (NK)/T-cell lymphomas in Taiwan and the distribution and relative frequency of each subtype according to the new WHO classification, the pathology file of a medical center in southern Taiwan during 1989-2002 was retrospectively ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001625881

    authors: Lu D,Lin CN,Chuang SS,Hwang WS,Huang WT

    更新日期:2004-05-01 00:00:00

  • FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes.

    abstract::Forty patients, with mainly poor risk haematological malignancies, were given the new regimen FLAG, comprising fludarabine, arabinosyl cytosine and G-CSF. Twenty four patients had acute myeloid leukaemia (AML), 8 patients myelodysplastic syndrome (MDS) and a further 8 patients had a variety of other haematological mal...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709068275

    authors: Nokes TJ,Johnson S,Harvey D,Goldstone AH

    更新日期:1997-09-01 00:00:00

  • Preferential expression of phosphatidylglucoside along neutrophil differentiation pathway.

    abstract::Phosphatidylglucoside (PtdGlc), a new type of glycolipid, was recently identified. We examined PtdGlc expression in normal blood cells and leukemic cells using an anti-PtdGlc monoclonal antibody, DIM-21. Neutrophils, monocytes, HL-60 cells and a subset of cord blood (CB) CD34(+) cells, but not erythroblasts, expressed...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190902934928

    authors: Oka S,Nagatsuka Y,Kikuchi J,Yokote T,Hirabayashi Y,Hanafusa T,Ozawa K,Muroi K

    更新日期:2009-07-01 00:00:00

  • Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment.

    abstract::Syndecan-1 is a transmembrane proteoglycan expressed on the surface of tumor cells of various origins including myeloma, Hodgkin's disease, and certain human immunodeficiency virus (HIV) associated lymphomas. Functional studies in myeloma reveal that syndecan-1 may act as a multifunctional regulator of cell behavior i...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199909083378

    authors: Dhodapkar MV,Sanderson RD

    更新日期:1999-06-01 00:00:00

  • Prognostic significance of T-lineage leukemic cell growth in SCID mice: a Children's Cancer Group study.

    abstract::Contemporary intensive therapies are effective for the majority of pediatric T-lineage acute lymphoblastic leukemia (ALL) patients, thus current challenge is to identify patients who may benefit from alternative treatment modalities. Previously, we demonstrated that human leukemic cell growth in the severe combined im...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909058405

    authors: Uckun FM,Waurzyniak BJ,Sather HN,Sensel MG,Chelstrom L,Nachman J,Gaynon PS,Bostrom B,Ek O,Sarquis M,Steinherz PG,Reaman GH

    更新日期:1999-02-01 00:00:00

  • Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.

    abstract::The clinical significance and mechanisms of TET2 are not well defined in myeloid malignancies. We detected TET2 mutations and assayed its catalyzing conversion product 5-hydroxymethylcytosine (5-hmC) in 61 Chinese patients with MDS. Ten patients were identified to have TET2 mutations (16.4%). 5-hmC levels in patients ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.778408

    authors: Liu X,Zhang G,Yi Y,Xiao L,Pei M,Liu S,Luo Y,Zhong H,Xu Y,Zheng W,Shen J

    更新日期:2013-11-01 00:00:00

  • Role of hepatocyte growth factor in hemopoiesis.

    abstract::Hepatocyte growth factor (HGF) is a polypeptide that stimulates proliferation, motility, and morphogenesis of various cells, particularly epithelial cells. There is considerable evidence that HGF is a regulator in hemopoiesis not only in mice but also in humans. In mice, HGF and c-met (its receptor) mRNA are coexpress...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199609054832

    authors: Ikehara S

    更新日期:1996-10-01 00:00:00

  • DNA ploidy analysis as an adjunct for the detection of relapse in B-lineage acute lymphoblastic leukemia.

    abstract::Detection of relapse in acute lymphoblastic leukemia (ALL) is essential for proper management. However, immunophenotypic detection of relapse by flow cytometry in B-lineage ALL can be confounded by several factors, including lack of a unique immunophenotype and modulation of aberrant phenotypes after treatment. We hyp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701760052

    authors: Kenney B,Zieske A,Rinder H,Smith B

    更新日期:2008-01-01 00:00:00

  • Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western Australia.

    abstract::We present an analysis of 98 consecutive patients with peripheral T-cell lymphoma (PTCL) treated over a 10-year period within Western Australia. The most common frontline therapies were CHO(E)P (47%), HyperCVAD (21%), and reduced intensity therapy or supportive care alone (19%). Median and 4-year overall survival (OS)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1637865

    authors: Kuzich JA,Hutchison AP,Lim KJC,Smallbone P,Denning K,Wright MP,Cull G,Leahy MF,Joske DJL,Radeski D,Purtill D

    更新日期:2019-12-01 00:00:00

  • Study of the S427G polymorphism and of MYBL2 variants in patients with acute myeloid leukemia.

    abstract::Dysregulation of MYBL2 has been associated to tumorigenesis and the S427G polymorphism could induce partial inactivation of MYBL2, associating it with cancer risk. It has previously been shown that MYBL2 was over-expressed in some acute myeloid leukemias (AML), portending poor prognosis. However, to date no studies ha...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1049167

    authors: Dolz S,García P,Llop M,Fuster Ó,Luna I,Ibáñez M,Gómez I,López M,Such E,Cervera J,Sanz MA,De Juan I,Palanca S,Murria R,Bolufer P,Barragán E

    更新日期:2016-02-01 00:00:00

  • Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease.

    abstract::Although associations between autoimmune disorders (AIs) and the development of myeloid neoplasms have been described, the pathologic features and natural history of these malignancies have not been well characterized. We evaluated whether patients with AIs with acute myeloid leukemia (AML) were similar in nature to p...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.736982

    authors: DiNardo CD,Ogdie A,Hexner EO,Frey NV,Loren AW,Luger SM

    更新日期:2013-06-01 00:00:00

  • Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.

    abstract::Nilotinib has shown favorable safety in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic (CML-CP) or accelerated phase (CML-AP) who failed prior imatinib, and superior efficacy over imatinib in newly diagnosed Ph+ patients with CML-CP. Reported here are the efficacy and sa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2011.627480

    authors: Nicolini FE,Masszi T,Shen Z,Gallagher NJ,Jootar S,Powell BL,Dorlhiac-Llacer PE,Zheng M,Szczudlo T,Turkina A

    更新日期:2012-05-01 00:00:00

  • Gaucher disease and multiple myeloma.

    abstract::Gaucher disease (GD) is the most frequent lysosomal storage disease and corresponds to an inherited deficiency of glucocerebrosidase. Due to excessive accumulation of glucocerebroside in bone marrow, both cytopenia and bone lesions may occur. The incidence of malignant disorders has been evoked in non-neuronopathic ty...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190600565453

    authors: Costello R,O'Callaghan T,Sébahoun G

    更新日期:2006-07-01 00:00:00

  • Randomized study of granulocyte colony stimulating factor for childhood B-cell non-Hodgkin lymphoma: a report from the Japanese pediatric leukemia/lymphoma study group B-NHL03 study.

    abstract::The objective of this study was to assess the impact of the primary prophylaxis of granulocyte colony-stimulating factor (G-CSF) in the management of childhood B-cell non-Hodgkin lymphoma (B-NHL). Patients with advanced-stage mature B-NHL were randomized to receive prophylactic G-CSF (G-CSF+) or not receive G-CSF (G-C...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,随机对照试验

    doi:10.3109/10428194.2015.1106534

    authors: Tsurusawa M,Watanabe T,Gosho M,Mori T,Mitsui T,Sunami S,Kobayashi R,Fukano R,Tanaka F,Fujita N,Inada H,Sekimizu M,Koh K,Kosaka Y,Komada Y,Saito AM,Nakazawa A,Horibe K,lymphoma committee of the Japanese Pediatric Leuke

    更新日期:2016-07-01 00:00:00

  • Richter's syndrome in the brain first manifested as an ischaemic stroke.

    abstract::Isolated central nervous system involvement in Richter's syndrome (RS) is extremely rare and only 6 such cases have been described, so far. We report a 60-year-old woman with B-cell chronic lymphocytic leukemia (B-CLL) heavily pretreated with cladribine based regimens and rituximab in whom RS in the brain was first ma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001638823

    authors: Robak T,Góra-Tybor J,Tybor K,Jamroziak K,Robak P,Kordek R,Rieske P,Majos A,Urbańska-Ryś H

    更新日期:2004-06-01 00:00:00

  • Serum interleukin-6 levels in patients with thrombocytosis.

    abstract::Interleukin-6 (IL-6) has been shown to increase platelet counts in several animal models and to enhance megakaryocytopoiesis in vitro. In order to investigate the possible relationship between IL-6 and thrombocytosis, serum IL-6 levels in patients with platelet counts > or = 6 x 10(5)/microliters were measured using a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199209054910

    authors: Hollen CW,Henthorn J,Koziol JA,Burstein SA

    更新日期:1992-10-01 00:00:00

  • Analysis of Wilms tumor gene (WT1) expression in acute leukemia patients with special reference to the differential diagnosis between eosinophilic leukemia and idiopathic hypereosinophilic syndromes.

    abstract::Continuous Wilms' tumor gene (WT1) expression is a typical feature of leukemic blasts in AML, ALL, and blast crisis CML patients. It is easily detectable by a variety of RT-PCR protocols, which differ mainly in their sensitivity. The nuclear WT1 protein can be found in blasts of approximately 50-60% of acute leukemia ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009148849

    authors: Menssen HD,Schmidt A,Bartelt S,Arjomand A,Thomsen H,Leben R,Kath R,Thiel E

    更新日期:2000-01-01 00:00:00

  • Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma.

    abstract::Pixantrone is a potentially more effective, less cardiotoxic alternative to doxorubicin for patients with aggressive non-Hodgkin lymphoma (aNHL). This phase I/II non-comparative study evaluated pixantrone in place of doxorubicin in the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone),...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.546016

    authors: Borchmann P,Herbrecht R,Wilhelm M,Morschhauser F,Hess G,Cernohous P,Veals SA,Singer JW,Engert A

    更新日期:2011-04-01 00:00:00

  • The influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation.

    abstract::Lymphoid recovery following myeloablative stem cell transplantation (SCT) displays a logistic pattern of exponential growth followed by a plateau. Within this logistic framework, lymphoid recovery is characterized by the parameters R (slope of ascent), a (time of maximal rate of ascent) and K (plateau), the 'steady-st...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1452216

    authors: Kobulnicky DJ,Sabo RT,Sharma S,Shubar Ali AS,Kobulnicky KM,Roberts CH,Clark WB,Chung HM,McCarty JM,Toor AA

    更新日期:2018-12-01 00:00:00

  • Abnormal expression of CD66a promotes proliferation and inhibits apoptosis of human leukemic B cells in vitro.

    abstract::The aberrant expression of myeloid antigen CD66 on acute B-lymphoblastic leukemia (B-ALL) cells is a well-documented phenomenon. CD66a is a major subtype of the CD66 family which plays a dual role in different cancers, and the contradictory effect may depend on the isoform ratio of CD66a-4L to CD66a-4S. Although the a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.913287

    authors: Zhao W,Zhang Y,Liu D,Zhong L,He Q,Zhao Y

    更新日期:2015-01-01 00:00:00

  • Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature.

    abstract::Isochromosome 17q [i(17q)] is frequently observed in the blast crisis (BC) of chronic myelogenous leukemia (CML). It has been suggested that this chromosome abnormality is associated with special hematological characteristics of the BC, but the information on this subject is scarce. The clinical, hematological and cyt...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009060321

    authors: Hernández-Boluda JC,Cervantes F,Costa D,Carrió A,Montserrat E

    更新日期:2000-06-01 00:00:00

  • The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells.

    abstract::Acute myeloid leukemia (AML) is a clonal malignant disease characterized by an increasing number of immature myeloid cells arrested at various stages of granulocytic and monocytic differentiation. The stage of the blockage defines distinct AML subtypes (AML1 to AML5 are the most frequent ones). There is increasing evi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819042000206687

    authors: Gadhoum Z,Delaunay J,Maquarre E,Durand L,Lancereaux V,Qi J,Robert-Lezenes J,Chomienne C,Smadja-Joffe F

    更新日期:2004-08-01 00:00:00

  • Variant and masked translocations in acute promyelocytic leukemia.

    abstract::Acute promyelocytic leukemia (APL) is characterized by a unique hemorrhagic syndrome, disseminated intravascular coagulation, and the association with the specific (15;17 chi q22-23:q12-21) translocation, which disrupts the retinoic acid receptor alpha (RARA) and the promyelocytic leukemia (PML) genes. The t(15;17) le...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199609051752

    authors: Brunel V,Lafage-Pochitaloff M,Alcalay M,Pelicci PG,Birg F

    更新日期:1996-07-01 00:00:00

  • Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy.

    abstract::We describe an HIV-infected 44-year-old man who presented 1 month after discontinuation of HAART therapy with a large mass extending from the mediastinum, enclosing the heart and extending through the diaphragm to the epigastric region. Biopsies subsequently revealed a highly aggressive non-Hodgkin's lymphoma (NHL) pr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290006260

    authors: Nasta SD,Carrum GM,Shahab I,Hanania NA,Udden MM

    更新日期:2002-02-01 00:00:00

  • Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation.

    abstract::B-cell chronic lymphocytic leukemia (CLL) is a clonal B cell malignancy of morphologically mature, functionally immature B cells. B-cell CLL cells are known to be resistant to killing by anticancer and other agents. This resistance is associated with alterations in apoptosis and cell cycle regulated genes. In our earl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000006411

    authors: Wang P,Pavletic ZS,Joshi SS

    更新日期:2002-09-01 00:00:00

  • Deletion of CDKN2A/B is associated with inferior relapse free survival in pediatric B cell acute lymphoblastic leukemia.

    abstract::Considering conflicting data on CDKN2A/B deletion in ALL, this study to assess its prognostic significance as an independent marker in a total of 96 pediatric B and T-ALL cases was planned. The overall frequency of CDKN2A/B deletion was 44% (n = 43) with 36% (30/83) in B-ALL and 100% (13/13) in T-ALL. CDKN2A/B deletio...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1482542

    authors: Kathiravan M,Singh M,Bhatia P,Trehan A,Varma N,Sachdeva MS,Bansal D,Jain R,Naseem S

    更新日期:2019-02-01 00:00:00

  • Pathways and mechanisms of venetoclax resistance.

    abstract::The approval of venetoclax, a 'BH3-mimetic' antagonist of the BCL-2 anti-apoptotic protein, for chronic lymphocytic leukemia represents a major milestone in translational apoptosis research. Venetoclax has already received 'breakthrough' designation for acute myeloid leukemia, and is being studied in many other tumor ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1283032

    authors: Bose P,Gandhi V,Konopleva M

    更新日期:2017-09-01 00:00:00

  • Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.

    abstract::BCL6 is a transcriptional repressor often expressed constitutively in diffuse large B-cell lymphomas (DLBCL) due to mutations of its genomic locus. BCL6 mediates aberrant survival, proliferation, genomic instability and differentiation blockade in DLBCL cells. The biochemical study of BCL6 mediated gene repression has...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190801895345

    authors: Parekh S,Privé G,Melnick A

    更新日期:2008-05-01 00:00:00

  • Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.

    abstract::We investigated the role of the leptin receptor (Ob-R) and its relationship with PI3K/AKT activation in diffuse large B-cell lymphoma (DLBCL) clinical samples followed by in vitro studies using a panel of CRC cell lines. Leptin exerts its physiological action through its receptor Ob-R. Overexpression of Ob-R has been ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428191003802365

    authors: Uddin S,Bu R,Ahmed M,Hussain AR,Ajarim D,Al-Dayel F,Bavi P,Al-kuraya KS

    更新日期:2010-07-01 00:00:00

  • DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.

    abstract::This single institution cohort study of 132 AML patients investigated the clinical implications of co-mutations detected with a 42-gene NGS panel. In the intermediate-risk cytogenetic group, FLT3-ITD is an adverse prognostic indicator only in the presence of a DNMT3A co-mutation, regardless of NPM1 mutation status. In...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1397659

    authors: Ma J,Dunlap J,Paliga A,Traer E,Press R,Shen L,Fan G

    更新日期:2018-08-01 00:00:00